Indivior PLC (NASDAQ:INDV) Sees Significant Increase in Short Interest

Indivior PLC (NASDAQ:INDV) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,220,000 shares, a growth of 9.9% from the December 31st total of 1,110,000 shares. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is currently 1.0 days. Approximately 1.1% of the shares of the stock are sold short.

Institutional Trading of Indivior

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Indivior during the 4th quarter worth approximately $56,000. Stifel Financial Corp acquired a new position in Indivior in the 3rd quarter valued at about $100,000. Melqart Asset Management UK Ltd purchased a new position in Indivior in the 3rd quarter valued at about $132,000. Jane Street Group LLC purchased a new position in Indivior in the 3rd quarter valued at about $180,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after purchasing an additional 6,121 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analyst Ratings Changes

INDV has been the subject of several research analyst reports. Rodman & Renshaw assumed coverage on Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th. Craig Hallum lowered their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th. Finally, RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th.

Indivior Trading Down 1.4 %

Shares of NASDAQ:INDV traded down $0.17 during midday trading on Monday, hitting $11.73. 956,665 shares of the stock were exchanged, compared to its average volume of 1,110,775. The stock has a market cap of $1.62 billion, a P/E ratio of -293.18 and a beta of 0.74. Indivior has a twelve month low of $7.33 and a twelve month high of $23.22. The company has a 50 day moving average price of $11.80 and a 200-day moving average price of $11.05.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.